Slc17A6 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
| VGLUT2 |
|---|
| Gene Symbol | SLC17A6 |
| UniProt ID | Q9P1U1 |
| PDB ID | 5W5U, 6E7K |
| Molecular Weight | 65.4 kDa |
| Subcellular Localization | Synaptic vesicle membrane, presynaptic terminal |
| Protein Family | SLC17 family (vesicular glutamate transporters) |
Vesicular Glutamate Transporter 2 (VGLUT2), encoded by the SLC17A6 gene, is a proton-coupled glutamate transporter that packages glutamate into synaptic vesicles. VGLUT2 is the primary vesicular glutamate transporter in subpopulations of excitatory neurons throughout the brain, particularly in thalamus, brainstem, and subcortical structures. By mediating glutamate uptake into synaptic vesicles, VGLUT2 is essential for glutamatergic neurotransmission and is implicated in various neurological and neurodegenerative disorders.
¶ Domain Architecture
VGLUT2 contains 12 transmembrane domains characteristic of the SLC17 family:
- N-terminus: Cytoplasmic, contains trafficking signals
- Transmembrane helices 1-12: Form the translocation pathway
- Extracellular loops: Loop C contains key substrate-binding residues
- C-terminus: Cytoplasmic, contains PDZ-binding motif
VGLUT2 uses a proton gradient to drive glutamate uptake:
- Proton binding: Protons from the vesicular lumen bind to VGLUT2
- Glutamate binding: Cytoplasmic glutamate binds to the transporter
- Conformational change: Transporter shifts from outward to inward-facing
- Release: Glutamate and protons released into the vesicle lumen
- Recycling: Transporter returns to initial state
| Substrate |
Affinity (Km) |
Notes |
| L-Glutamate |
~0.3 mM |
Primary substrate |
| L-Aspartate |
~2 mM |
Minor substrate |
| N-Acetylaspartylglutamate |
~1 mM |
Co-released |
VGLUT2 is essential for packing glutamate into synaptic vesicles[^3]:
- Vesicular loading: Concentrates glutamate ~10,000-fold in vesicles
- Quantal size: Determines glutamate amount per vesicle
- Synaptic efficacy: VGLUT2 expression level affects transmission strength
- Co-transmission: May package other neuromodulators
VGLUT2 is expressed in glutamatergic neurons:
- Thalamus: All thalamic relay neurons
- Brainstem: Pontine nuclei, inferior olive, red nucleus
- Subcortical structures: Basal ganglia output nuclei
- Cerebellum: Granule cells (VGLUT1 also)
- Hypothalamus: Several nuclei
- Cortex: Layer 5 pyramidal cells (some)
| VGLUT |
Primary Expression |
Function |
| VGLUT1 |
Cortex, hippocampus |
Major cortical VGLUT |
| VGLUT2 |
Thalamus, brainstem |
Major subcortical VGLUT |
| VGLUT3 |
Cholinergic, serotonergic |
Non-classical VGLUT |
- Embryonic: Early expression in developing brain
- Postnatal: Increases dramatically around P10-14
- Adult: Stable expression in mature neurons
- Synaptic vesicles: Concentrated in clear synaptic vesicles
- Presynaptic active zone: Near release sites
- Dendrites: Dendritic vesicle pools in some neurons
VGLUT2 alterations in AD[^4]:
- Glutamatergic dysfunction: Altered VGLUT2 in AD thalamus
- Excitotoxicity: May contribute to excitotoxic damage
- Thalamic involvement: Early thalamic pathology in AD
- Thalamic changes: VGLUT2 neurons in PD thalamus affected
- Excessive glutamate: Potential contributor to dyskinesia
- Subthalamic nucleus: High VGLUT2 expression
- Motor neuron vulnerability: VGLUT2 in ALS models
- Excitotoxic mechanisms: Glutamate dysregulation
- Therapeutic target: VGLUT2 modulators in development
- Seizure susceptibility: Altered VGLUT2 expression
- Glutamate homeostasis: Imbalance contributes to seizures
- Therapeutic potential: VGLUT2 as target
| Approach |
Mechanism |
Status |
| VGLUT2 inhibitors |
Reduce glutamate release |
Preclinical |
| Proton gradient modulators |
Affect VGLUT2 activity |
Research |
| Gene therapy |
Modulate expression |
Research |
- Essential function: Complete loss is lethal
- Expression pattern: Broad throughout brain
- Compensation: Other VGLUTs can compensate
- VGLUT2 knockout mice: Die shortly after birth
- Conditional knockouts: Reveal region-specific functions
- Heterozygotes: Viable, show subtle deficits
- Single-cell sequencing: VGLUT2 neuron subtypes
- Circuit mapping: Input-output relationships
- Disease biomarkers: VGLUT2 as indicator
- Optogenetics: VGLUT2 promoter for targeting
The study of Slc17A6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.